Dr. Carolyn Britten on Next Steps in Immunotherapy

Carolyn D. Britten, MD
Published: Tuesday, Sep 15, 2015



Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
 
Immunotherapy offers a lot of promise to the field of oncology, says Britten, but it is not the only option. Other types of novel therapies are necessary.  
 
Proper patient selection will be the key to best utilizing immune checkpoint blockage therapies, she says. A better understanding of which combinations work best is also needed.     


Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
 
Immunotherapy offers a lot of promise to the field of oncology, says Britten, but it is not the only option. Other types of novel therapies are necessary.  
 
Proper patient selection will be the key to best utilizing immune checkpoint blockage therapies, she says. A better understanding of which combinations work best is also needed.     



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x